BI Asset Management Fondsmaeglerselskab’s Sarepta Therapeutics SRPT Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,301	Closed	-$657K	–	519
2021 Q4	$657K	Hold	7,301	–	–	0.02%	302
2021 Q3	$675K	Hold	7,301	–	–	0.03%	295
2021 Q2	$568K	Hold	7,301	–	–	0.02%	331
2021 Q1	$544K	Buy	7,301 +2,431	+50%	+$224K	0.02%	312
2020 Q4	$830K	Sell	4,870 -133	-3%	-$19.7K	0.04%	258
2020 Q3	$703K	Sell	5,003 -198	-4%	-$30.1K	0.03%	326
2020 Q2	$834K	Buy	+5,201	New	+$708K	0.04%	296
2020 Q1	–	Sell	-225	Closed	-$29K	–	384
2019 Q4	$29K	Sell	225 -528	-70%	-$53.3K	﹤0.01%	310
2019 Q3	$57K	Buy	+753	New	+$88.9K	﹤0.01%	351

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's SRPT Position: Q1 2022 in Review

BI Asset Management Fondsmaeglerselskab sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 7,301 shares — an estimated $657K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in SRPT in Q3 2019 and held it in 9 quarters. The position peaked at $834K in Q2 2020. 329 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

BI Asset Management Fondsmaeglerselskab reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
BI Asset Management Fondsmaeglerselskab sold 7,301 Sarepta Therapeutics shares in Q1 2022, an estimated $657K.
BI Asset Management Fondsmaeglerselskab first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 9 quarters.
BI Asset Management Fondsmaeglerselskab's Sarepta Therapeutics position peaked at $834K in Q2 2020.
329 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q1 2022, filed 11 May 2022.